Tubeless Insulin Pump Market: By Type (Animas Insulin Pumps, Medtronic Insulin Pumps), By End-use (Homecare, Hospitals, Clinics), and Geography

Tubeless Insulin Pump Market was valued at USD 1,376.3 million in 2022 and is poised to grow at a significant CAGR of 24.9% from 2023-2029. Tubeless insulin pumps, also known as insulin patch pumps, are small, inconspicuous, and lightweight. These items are unobtrusive, low-cost, easily cling to the human body, and simple to use. According to the NCBI, individuals with type 1 diabetes prefer tubeless insulin pumps. These pumps now employ Nitinol wire, a spring, a step motor, a piezoelectric crystal, a manual pumping chamber, and a bladder for insulin administration. These tubeless insulin pumps come in a variety of sizes and technology. These items may be worn and handled successfully beneath garments. With an increase in diabetes incidence, particularly among older patients, the tubeless insulin pump market is expected to rise significantly in the future years. Based on end-use, the home care segment accounted for a significant market share of more than 76% in 2021 and is expected to drive the market growth during the forecast period owing to the rising use of these technologies in home care settings. Recent technological advances and the inclusion of innovative modalities have created a novel, user-friendly gadgets. The availability of these simple-to-use devices is expected to accelerate the growth of the tubeless insulin pump industry. These pumps typically include a tiny pod or patch containing insulin units in the reservoir and a personal diabetes therapeutics manager who assists in managing and adjusting insulin administration. One of the major reasons impacting the tubeless insulin pump market share is the significant growth in the number of diabetic patients. With an increasing patient population, the market is predicted to increase dramatically because of the growing desire for tubeless insulin pumps due to its dependability and reduced need for numerous injections.

Tubeless Insulin Pump Market Key Developments:
In August 2021, Insulet Corporation has received FDA permission to use Eli Lilly's Lyumjev injection in conjunction with Insulet's Omnipod Insulin Management System and Omnipod DASH Insulin Management System. This FDA clearance enabled the firm to provide more clinical options for diabetic patients to maintain their glucose levels and reduce post-meal increases.